Governing Real-World Health Data as a Public Utility

Key Takeaways

• Real-world health data remains fragmented and non‑interoperable
• Public‑utility model enforces standards and accountability
• Aligns financial incentives with data interoperability
• Enables continuous public oversight and auditability
• Accelerates research, clinical care, and public‑health decisions

Summary

The article proposes governing real‑world health data as a public utility, using federated, standards‑based, community‑driven models to overcome fragmentation, proprietary control, and weak oversight. It cites ARPA‑H’s interest in economic models and highlights existing distributed networks and research enclaves as building blocks. By imposing enforceable participation, aligned incentives, and continuous public oversight, the framework aims to unlock data for research, clinical care, and public‑health decision‑making. Adoption could transform health‑data infrastructure into essential public‑good infrastructure.

Pulse Analysis

The surge of real‑world health data generated by hospitals, wearables, and insurance claims has outpaced the mechanisms needed to turn it into actionable insight. While these datasets promise breakthroughs in precision medicine and post‑market safety, they are scattered across proprietary platforms, lack common standards, and are governed by voluntary agreements that can be ignored. This fragmentation slows the translation of research findings into clinical guidelines and hampers rapid public‑health responses, underscoring a systemic gap in the United States and beyond and regulatory bodies.

Proponents argue that treating health data as a public utility can resolve these shortcomings. A utility framework imposes enforceable participation, mandates interoperable standards, and places stewardship under continuous public oversight, creating transparent audit trails that rebuild patient trust. By aligning financial incentives with shared infrastructure, vendors are compensated for maintaining compatible systems rather than competing on closed silos. The model also leverages existing distributed data networks and research enclaves, allowing them to operate under a unified legal and economic regime that encourages broad, equitable access and public accountability.

Adopting a health‑data public utility could reshape the biotech and pharma landscape, accelerating drug safety monitoring and enabling real‑time epidemiological modeling. Policymakers, including ARPA‑H, are already soliciting economic models that balance public benefit with vendor compensation, signaling momentum toward regulatory reform. Internationally, the approach offers a template for nations grappling with similar data silos, fostering cross‑border collaborations. As the ecosystem matures, stakeholders that invest early in interoperable platforms stand to gain competitive advantage while contributing to a more resilient, patient‑centric health system for future pandemics.